NASDAQ:ARGX

argenx (ARGX) Stock Forecast, Price & News

$491.63

+5.67 (+1.17%)

(As of 04:31 PM ET)

Compare

Today's Range: $485.55
▼
$496.14
50-Day Range: $477.79
▼
$548.43
52-Week Range: $333.07
▼
$550.76

Volume: 272,427 shs
Average Volume: 250,441 shs
Market Capitalization: $28.78 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $519.55

argenx MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.76 Rating Score
Upside/Downside: 5.4% Upside
$519.55 Price Target
Short Interest: Healthy
1.12% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.95
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($5.10) to ($3.03) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

620th out of 972 stocks

Biological Products, Except Diagnostic Industry

92nd out of 158 stocks

2.4

Analyst's Opinion

Consensus Rating
argenx has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on 17 buy ratings, 3 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $519.55, argenx has a forecasted upside of 5.4% from its current price of $492.78.
Amount of Analyst Coverage
argenx has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
1.12% of the outstanding shares of argenx have been sold short.
Short Interest Ratio / Days to Cover
argenx has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in argenx has recently decreased by 6.51%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
argenx does not currently pay a dividend.
Dividend Growth
argenx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ARGX.

2.8

News and Social Media Coverage

News Sentiment
argenx has a news sentiment score of 0.95. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for argenx this week, compared to 4 articles on an average week.
Search Interest
Only 3 people have searched for ARGX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
4 people have added argenx to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, argenx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.43% of the stock of argenx is held by insiders.
Percentage Held by Institutions
52.77% of the stock of argenx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for argenx are expected to grow in the coming year, from ($5.10) to ($3.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of argenx is -68.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of argenx is -68.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
argenx has a P/B Ratio of 9.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About argenx (NASDAQ:ARGX) Stock

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC. The company is also developing ARGX-109 and ARGX-116; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; and ARGX-114, an antibody directed against the mesenchymal-epithelial transition factor receptor. In addition, its partnered product candidates include Cusatuzumab for treatment of acute myeloid leukemia; ARGX-115 for the treatment of cancer; and ARGX-112 to treat interleukin-22 receptor. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., Staten Biotechnology B.V., and Shire International GmbH. It also has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

ARGX Price History

30 days | 90 days | 365 days | Advanced Chart

ARGX Stock News Headlines

September 25, 2023 | marketbeat.com

Argenx's 28% Surge & Promising Product Propel Investor Confidence

Argenx's chart is forming a bullish base after a 28% jump after positive clinical trials. Analysts believe the immunology specialist is an acquisition target.

September 26, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX) and Pliant Therapeutics (PLRX)

September 29, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 21, 2023 | nasdaq.com

Argenx's Vyvgart Authorized For Sale In Canada For Generalized Myasthenia Gravis

September 21, 2023 | finance.yahoo.com

argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis

September 19, 2023 | americanbankingnews.com

argenx's (ARGX) Buy Rating Reiterated at HC Wainwright

September 15, 2023 | msn.com

How IBD Stock Of The Day Argenx, A Top-Notch Biotech, Is Dominating — With One Drug

September 15, 2023 | markets.businessinsider.com

Argenx: CHMP Recommends EC Approval For Subcutaneous Efgartigimod For Generalized Myasthenia Gravis

September 29, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

September 15, 2023 | finance.yahoo.com

argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis

August 31, 2023 | markets.businessinsider.com

What 20 Analyst Ratings Have To Say About argenx

August 30, 2023 | benzinga.com

Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today

August 22, 2023 | thestreet.com

argenx SE

August 21, 2023 | finance.yahoo.com

Should You Consider Adding argenx SE (ARGX) to Your Portfolio?

August 11, 2023 | benzinga.com

Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years

August 8, 2023 | finance.yahoo.com

Is Argenx Stock a Buy Now?

August 4, 2023 | seekingalpha.com

argenx: Three Important Milestones Reached In 2023, More To Come

August 1, 2023 | msn.com

Argen X SE - ADR (ARGX) Price Target Increased by 16.79% to 551.80

August 1, 2023 | markets.businessinsider.com

Stifel Nicolaus Reaffirms Their Buy Rating on Argenx Se (ARGX)

August 1, 2023 | benzinga.com

$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today

July 29, 2023 | msn.com

Argenx Beats Q2 Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260%

July 28, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: West Pharmaceutical Services (WST), Argenx Se (ARGX) and HCA Healthcare (HCA)

July 28, 2023 | msn.com

Argenx Beats Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260%

July 27, 2023 | seekingalpha.com

argenx SE 2023 Q2 - Results - Earnings Call Presentation

July 27, 2023 | finanznachrichten.de

argenx SE: argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

July 27, 2023 | benzinga.com

argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update

July 27, 2023 | msn.com

Argenx Stock Rides 'Megabuster' Drug Excitement To 40% Gain Before Earnings

See More Headlines

Receive ARGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.

ARGX Company Calendar

Last Earnings: 7/27/2023
Today: 9/29/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ARGX
CUSIP: N/A
CIK: 1697862
Web: www.argenx.com
Phone: (176) 303-0488
Fax: N/A
Employees: 843
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $519.55
High Stock Price Forecast: $609.00
Low Stock Price Forecast: $246.00
Forecasted Upside/Downside: +5.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.76
Research Coverage: 21 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.17)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-709,590,000.00
Net Margins: -47.28%
Pretax Margin: -52.69%
Return on Equity: -27.99%
Return on Assets: -25.09%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.47
Quick Ratio: 7.84

Sales & Book Value

Annual Sales: $445.27 million
Price / Sales: 64.82
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $50.79 per share
Price / Book: 9.71

Miscellaneous

Outstanding Shares: 58,540,000
Free Float: 57,115,000
Market Cap: $28.86 billion
Optionable: Optionable
Beta: 0.75

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Timothy Van Hauwermeiren EMBA (Age 51)
M.B.A., M.Sc., MSc, CEO & Exec. Director
Comp: $1.44M

Mr. Karl Gubitz (Age 53)
Chief Financial Officer

Ms. Malini Moorthy (Age 53)
Gen. Counsel

Mr. Arjen Lemmen M.Sc. (Age 38)
VP of Corp. Devel. & Strategy

Ms. Andria Wilk (Age 49)
Global Head of Quality

Mr. Luc Truyen (Age 58)
Chief Medical Officer

Ms. Karen Massey (Age 44)
Chief Operating Officer

Mr. Filip Borgions
VP & Global Head of Technical Operations

Mr. Peter Ulrichts (Age 43)
Chief Scientific Officer

Ms. Beth DelGiacco
VP and Global Head of Corp. Communications & Investor Relations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ARGX Stock - Frequently Asked Questions

Should I buy or sell argenx stock right now?: 21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last year. There are currently 1 sell rating, 3 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARGX shares.
View ARGX analyst ratings or view top-rated stocks.
What is argenx's stock price forecast for 2023?: 21 analysts have issued 12 month price objectives for argenx's shares. Their ARGX share price forecasts range from $246.00 to $609.00. On average, they expect the company's share price to reach $519.55 in the next year. This suggests a possible upside of 5.4% from the stock's current price.
View analysts price targets for ARGX or view top-rated stocks among Wall Street analysts.
How have ARGX shares performed in 2023?: argenx's stock was trading at $378.83 on January 1st, 2023. Since then, ARGX shares have increased by 30.1% and is now trading at $493.00.
View the best growth stocks for 2023 here.
Are investors shorting argenx?: argenx saw a decline in short interest in the month of September. As of September 15th, there was short interest totaling 655,800 shares, a decline of 6.5% from the August 31st total of 701,500 shares. Based on an average daily volume of 302,700 shares, the short-interest ratio is presently 2.2 days.
View argenx's Short Interest.
When is argenx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our ARGX earnings forecast.
How were argenx's earnings last quarter?: argenx SE (NASDAQ:ARGX) posted its quarterly earnings results on Thursday, July, 27th. The company reported ($1.69) EPS for the quarter, meeting analysts' consensus estimates of ($1.69). The company earned $281.16 million during the quarter, compared to the consensus estimate of $258.32 million. argenx had a negative net margin of 47.28% and a negative trailing twelve-month return on equity of 27.99%. During the same period in the previous year, the company earned ($3.81) EPS.
What ETFs hold argenx's stock?: ETFs with the largest weight of argenx (NASDAQ:ARGX) stock in their portfolio include VanEck Biotech ETF (BBH), Fidelity Disruptive Medicine ETF (FMED), First Trust NYSE Arca Biotechnology Index Fund (FBT), BlackRock Future Health ETF (BMED), AdvisorShares Dorsey Wright ADR ETF (AADR), Simplify Health Care ETF (PINK), iShares Biotechnology ETF (IBB) and American CenturyFocused Dynamic Growth ETF (FDG).

What other stocks do shareholders of argenx own?: Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).
When did argenx IPO?: (ARGX) raised $65 million in an IPO on Thursday, May 18th 2017. The company issued 3,600,000 shares at a price of $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
What is argenx's stock symbol?: argenx trades on the NASDAQ under the ticker symbol "ARGX."
How do I buy shares of argenx?: Shares of ARGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is argenx's stock price today?: One share of ARGX stock can currently be purchased for approximately $493.00.
How much money does argenx make?: argenx (NASDAQ:ARGX) has a market capitalization of $28.86 billion and generates $445.27 million in revenue each year. The company earns $-709,590,000.00 in net income (profit) each year or ($7.17) on an earnings per share basis.
How many employees does argenx have?: The company employs 843 workers across the globe.
How can I contact argenx?: argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The official website for the company is www.argenx.com. The company can be reached via phone at (176) 303-0488 or via email at info@argenx.com.

This page (NASDAQ:ARGX) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial